Zetia vs Repatha: Side-Effect Profile Head-to-Head

How These Two Drugs Work Differently

Zetia and Repatha sit at opposite ends of the lipid-lowering pipeline. Understanding their mechanisms explains why their side-effect signatures diverge so sharply.

Ezetimibe: Blocking Cholesterol Absorption

Ezetimibe targets the Niemann-Pick C1-Like 1 (NPC1L1) protein on the brush border of small-intestine enterocytes. By blocking this transporter, the drug reduces dietary and biliary cholesterol absorption by roughly 54%. The liver compensates by upregulating LDL receptors, pulling more LDL out of the bloodstream. Net effect: an 18 to 22% drop in LDL-C as monotherapy, or an incremental 23 to 24% reduction when stacked on a statin [1].

Evolocumab: Disabling the LDL-Receptor Recycling Brake

Evolocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 normally tags hepatic LDL receptors for lysosomal degradation. By neutralizing PCSK9, evolocumab keeps more LDL receptors on the hepatocyte surface, producing LDL-C reductions of 59% on top of statin therapy [2]. The injectable route and biologic nature of the molecule create a side-effect profile distinct from small-molecule oral agents.

Why Mechanism Matters for Side Effects

A small oral molecule absorbed through the GI tract tends to produce GI-related adverse events. A subcutaneous monoclonal antibody tends to produce injection-site and immunologic reactions. This pharmacologic logic holds for both drugs.

Side-Effect Profiles: Trial-Level Data

No single randomized trial has compared ezetimibe directly against evolocumab. The safety comparison therefore draws from two landmark placebo-controlled outcome trials: IMPROVE-IT and FOURIER.

IMPROVE-IT Safety Data (Ezetimibe)

IMPROVE-IT enrolled 18,144 patients within 10 days of an acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg vs. Simvastatin 40 mg plus placebo. Median follow-up was 6 years [1].

Adverse events in the ezetimibe arm tracked closely with placebo:

• Gallbladder-related events: 3.1% ezetimibe vs. 3.5% placebo (no significant difference)
• Hepatitis or elevated ALT/AST >3× ULN: 2.5% vs. 2.3%
• Myopathy (CK >10× ULN with symptoms): 0.2% vs. 0.1%
• Rhabdomyolysis: <0.1% in both arms
• Cancer incidence: 10.2% vs. 10.2% (hazard ratio 1.00)
• Drug discontinuation due to adverse events: no statistically significant difference between arms

The FDA label for ezetimibe lists diarrhea (4.1%), upper respiratory infection (3.1%), and arthralgia (3.0%) as the most common treatment-emergent events from pooled Phase III data. Six years of IMPROVE-IT follow-up confirmed no delayed safety signals.

FOURIER Safety Data (Evolocumab)

FOURIER enrolled 27,564 patients with established atherosclerotic cardiovascular disease on optimized statin therapy and randomized them to evolocumab vs. Placebo. Median follow-up was 2.2 years [2].

Key adverse event rates:

• Injection-site reactions: 2.1% evolocumab vs. 1.6% placebo
• Myalgia: 4.0% vs. 3.6%
• Neurocognitive events (reported by patients): 1.6% vs. 1.5%
• New-onset diabetes: 8.1% vs. 7.7% (not statistically significant)
• Serious adverse events: 24.8% vs. 24.7%
• Discontinuation due to adverse events: 1.6% vs. 1.5%

The EBBINGHAUS cognitive sub-study (N=1,974), a prespecified FOURIER analysis, used validated neuropsychological testing and found no difference in cognitive function between evolocumab and placebo over 19 months, even among patients whose LDL-C fell below 25 mg/dL.

Head-to-Head Tolerability Comparison

Because direct comparison trial data do not exist, the table below synthesizes cross-trial findings. Rates are approximate and drawn from different populations.

| Adverse Event | Ezetimibe (IMPROVE-IT / label) | Evolocumab (FOURIER / label) | |---|---|---| | GI disturbance (diarrhea, nausea) | ~4% | ~2% | | Injection-site reaction | N/A (oral) | ~2.1% | | Myalgia / arthralgia | ~3% | ~4 to 5% | | Elevated transaminases (>3× ULN) | ~2.5% | <1% | | Neurocognitive complaints | Not reported as signal | ~1.6% (no objective deficit) | | Nasopharyngitis / URI | ~3% | ~5% | | New-onset diabetes signal | Not detected | Not statistically significant | | Discontinuation due to AEs | ~2% | ~1.6% |

What the Cross-Trial Data Tell Us

Both drugs show discontinuation rates nearly identical to their respective placebo arms. This is unusual for lipid-lowering agents and suggests genuine tolerability advantages over high-intensity statin monotherapy, where discontinuation rates in observational data reach 40 to 50% at two years.

Ezetimibe's side-effect burden leans GI. Evolocumab's leans musculoskeletal and injection-related. Neither drug produces the dose-dependent muscle toxicity that drives statin intolerance.

Muscle-Related Side Effects

Muscle complaints rank among the top reasons patients abandon lipid-lowering therapy. Both Zetia and Repatha offer a reprieve from statin-type myalgia, but the picture has nuance.

Ezetimibe and Myopathy Risk

Ezetimibe does not inhibit HMG-CoA reductase. Its myopathy signal in clinical trials is indistinguishable from placebo. The ACC/AHA 2018 cholesterol guideline recommends ezetimibe as first-line add-on for patients who cannot tolerate high-intensity statins but still need additional LDL lowering [3]. In practice, ezetimibe is often the drug given when a patient reports statin-related muscle pain.

Evolocumab and Myalgia Reports

FOURIER recorded myalgia in 4.0% of the evolocumab group vs. 3.6% on placebo. The GAUSS-3 trial specifically enrolled statin-intolerant patients and found that evolocumab produced muscle symptoms at rates comparable to placebo while ezetimibe showed a numerically higher rate of muscle-related adverse events than evolocumab in the same trial [4]. GAUSS-3 is one of the few studies that tested both drugs in a statin-intolerant population, though its open-label design and small size (N=511) limit direct comparison.

Practical Takeaway

For statin-intolerant patients, both drugs are reasonable options. Ezetimibe offers the simplicity of a daily pill. Evolocumab offers far greater LDL reduction. The 2018 ACC/AHA guideline positions ezetimibe as the initial add-on and PCSK9 inhibitors as escalation for patients who still fall short of their LDL target [3].

Injection-Site Reactions with Repatha

Injection-site reactions represent the most drug-specific side effect separating Repatha from Zetia. In FOURIER, 2.1% of patients on evolocumab reported injection-site reactions vs. 1.6% on placebo [2].

What Patients Experience

Reactions are typically mild: erythema, pain, or bruising at the injection site. Severe reactions are rare. The SureClick autoinjector and Pushtronex on-body infusor were designed to reduce injection discomfort, and real-world adherence data suggest that injection burden is a secondary concern behind cost for most patients who discontinue [5].

Comparison to Other Injectables

For context, the injection-site reaction rate with evolocumab (2.1%) is lower than rates seen with insulin glargine (~5%) and comparable to adalimumab (~3 to 4%). Patients already comfortable with self-injection, such as those managing diabetes, typically tolerate evolocumab without issue.

Long-Term Safety Considerations

The safety window differs between these two drugs. IMPROVE-IT provides 6 years of ezetimibe data. FOURIER's primary analysis covers 2.2 years, though the FOURIER-OLE (open-label extension) extends the safety record to approximately 5 years for a subset of patients [6].

Cancer Risk

IMPROVE-IT's 6-year cancer incidence was identical between arms: 10.2% vs. 10.2% [1]. The FOURIER-OLE reported no excess cancer signal through 5 years of follow-up [6]. Early pooled analyses of lipid-lowering trials had raised theoretical concerns about very low LDL and cancer. Both trials helped put that concern to rest.

Neurocognitive Safety

PCSK9 inhibitors can drive LDL-C below 20 mg/dL. Because the brain synthesizes its own cholesterol behind the blood-brain barrier, the hypothesis that very low circulating LDL impairs cognition has been tested repeatedly. The EBBINGHAUS sub-study found no cognitive decline in evolocumab-treated patients, including those achieving LDL-C <25 mg/dL. The Endocrine Society's 2020 scientific statement concluded: "Available evidence does not support a causal link between low LDL-C achieved with lipid-lowering therapy and neurocognitive dysfunction" [7].

Ezetimibe does not typically reduce LDL-C to levels that trigger this concern, making neurocognitive safety a non-issue for this drug.

Hepatic Safety

Ezetimibe carries a label warning for hepatic transaminase elevations, though the 2.5% rate in IMPROVE-IT was not significantly different from placebo. The FDA recommends checking liver enzymes when ezetimibe is co-administered with a statin. Evolocumab has no hepatotoxicity signal in any trial to date.

Immunogenicity

As a biologic, evolocumab carries a theoretical risk of anti-drug antibody formation. In FOURIER, binding antibodies developed in 0.3% of evolocumab-treated patients, and no neutralizing antibodies were detected [2]. This rate is clinically negligible.

Cost and Access as a Side-Effect Modifier

Side-effect profiles exist in a vacuum only on paper. In practice, cost shapes adherence, and non-adherence is the most dangerous "side effect" of any drug.

The Generic Advantage of Ezetimibe

Generic ezetimibe costs $15 to 30 per month at most retail pharmacies. Insurance coverage is nearly universal. This low barrier means patients are more likely to fill and refill the prescription, reducing the cardiovascular risk that comes with treatment gaps.

The Access Barrier for Evolocumab

Repatha's wholesale acquisition cost is approximately $5,850 per year. While Amgen offers copay assistance programs that can reduce out-of-pocket costs to as low as $5 per month for commercially insured patients, prior authorization requirements remain a significant barrier to PCSK9 inhibitor access. A 2018 analysis found that only 31% of prior authorization requests for PCSK9 inhibitors were approved on initial submission [8].

Non-adherence driven by cost or access delays exposes patients to the very cardiovascular events these drugs prevent. For a patient with established ASCVD and LDL-C still above goal on maximally tolerated statin plus ezetimibe, the "side effect" of not receiving evolocumab is continued residual cardiovascular risk.

Who Should Get Which Drug

The 2018 ACC/AHA guideline provides a clear algorithm [3]:

1. Maximize statin therapy (or use the highest tolerated intensity).
2. If LDL-C remains above threshold (≥70 mg/dL for very high-risk ASCVD), add ezetimibe.
3. If LDL-C remains above threshold on statin plus ezetimibe, add a PCSK9 inhibitor such as evolocumab.

This stepwise approach reflects both the side-effect data and the cost-effectiveness hierarchy. Ezetimibe is not "better" or "worse" than evolocumab. They occupy different rungs on the same treatment ladder.

For primary prevention patients without ASCVD, evolocumab is rarely indicated. Ezetimibe may be appropriate as statin add-on when LDL-C targets are not met.

For statin-intolerant patients, the GAUSS-3 data support either drug, with evolocumab producing greater LDL reduction [4]. The choice depends on the patient's baseline LDL-C, cardiovascular risk, and insurance formulary.

Current prescribing data from the 2022 ACC Expert Consensus Decision Pathway reinforce that ezetimibe should precede PCSK9 inhibitor initiation in most clinical scenarios because of its established safety record, oral convenience, and generic availability [9].